BHVN Quote, Financials, Valuation and Earnings

Dyne Therapeutics, Inc. has a net margin of -- compared to Biohaven Ltd.'s net margin of --. Biohaven Ltd.'s return on equity of -349.4% beat Dyne Therapeutics, Inc.'s return on equity of -64.85%.

Biohaven Ltd. has a consensus price target of $20.94, signalling upside risk potential of 84.31%. On the other hand Dyne Therapeutics, Inc. has an analysts' consensus of $39.13 which suggests that it could grow by 151.77%. Given that Dyne Therapeutics, Inc. has higher upside potential than Biohaven Ltd., analysts believe Dyne Therapeutics, Inc. is more attractive than Biohaven Ltd..

Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dyne Therapeutics, Inc. has a beta of 1.302, suggesting its more volatile than the S&P 500 by 30.201%.

Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dyne Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Dyne Therapeutics, Inc. pays out -- of its earnings as a dividend.

Biohaven Ltd. quarterly revenues are --, which are smaller than Dyne Therapeutics, Inc. quarterly revenues of --. Biohaven Ltd.'s net income of -$173.4M is lower than Dyne Therapeutics, Inc.'s net income of -$108M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Dyne Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus -- for Dyne Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -- compared to Biohaven Ltd.'s net margin of -301.29%. Biohaven Ltd.'s return on equity of -349.4% beat Nektar Therapeutics's return on equity of -327.67%.

Biohaven Ltd. has a consensus price target of $20.94, signalling upside risk potential of 84.31%. On the other hand Nektar Therapeutics has an analysts' consensus of $123.43 which suggests that it could grow by 73.04%. Given that Biohaven Ltd. has higher upside potential than Nektar Therapeutics, analysts believe Biohaven Ltd. is more attractive than Nektar Therapeutics.

Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.

Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Biohaven Ltd. quarterly revenues are --, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. Biohaven Ltd.'s net income of -$173.4M is lower than Nektar Therapeutics's net income of -$35.5M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 73.55x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics, Inc. has a net margin of -- compared to Biohaven Ltd.'s net margin of -834.87%. Biohaven Ltd.'s return on equity of -349.4% beat Protagonist Therapeutics, Inc.'s return on equity of 7.15%.

Biohaven Ltd. has a consensus price target of $20.94, signalling upside risk potential of 84.31%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $101.92 which suggests that it could grow by 25.07%. Given that Biohaven Ltd. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Biohaven Ltd. is more attractive than Protagonist Therapeutics, Inc..

Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.264, suggesting its more volatile than the S&P 500 by 126.409%.

Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend.

Biohaven Ltd. quarterly revenues are --, which are smaller than Protagonist Therapeutics, Inc. quarterly revenues of $4.7M. Biohaven Ltd.'s net income of -$173.4M is lower than Protagonist Therapeutics, Inc.'s net income of -$39.3M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Protagonist Therapeutics, Inc.'s PE ratio is 128.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 24.99x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Biohaven Ltd.'s net margin of 21.74%. Biohaven Ltd.'s return on equity of -349.4% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Biohaven Ltd. has a consensus price target of $20.94, signalling upside risk potential of 84.31%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 8.08%. Given that Biohaven Ltd. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Biohaven Ltd. is more attractive than Regeneron Pharmaceuticals, Inc..

Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biohaven Ltd. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Biohaven Ltd.'s net income of -$173.4M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 6.08x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.